- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Roxane Labs' generic prostate drug gets tentative approval from FDA
- FDA's Janet Woodcock not to retire
- Senate passes Drug Quality and Security Act
NEW YORK — Johnson & Johnson and the U.S. government are suing two generic drug makers to stop them from launching a generic drug for HIV, according to published reports.
Bloomberg reported Thursday that Tibotec, a subsidiary of J&J, and the government were separately suing Mylan and Lupin over a generic version of the drug Prezista (darunavir ethanolate), alleging patent infringement.
U.S. sales of Prezista were $290 million during the first nine months of this year, according to J&J sales data reported by Bloomberg. The last patent covering the drug expires in December 2026, according to the Food and Drug Administration.